DIRS.INFO The most relevant business & tech news

☆ JPMorgan downgrades Teva as generic medication business struggles
▼ + stars: | 2022-11-14 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Teva Pharmaceutical is hard to like as it continues to be weighed down by underperformance in some business areas, JPMorgan says. The new price target implies upside of just 5.5% from Friday's close. Schott noted the company has been able to continue paying down debt as a positive, but said it would need to continue allocating cash pay towards this. The stock's performance could be impacted by improvements in generics, a favorable opioid settlement or if the company is able to stave off competition on its migraine medication Ajovy. Teva shed 2.3% in the premarket and is up 18.4% compared with the start of the year.

☆ Weight loss startups offer access to new drugs, but do they provide good care?
▼ + stars: | 2022-11-13 | by ( Darius Tahir | Kaiser Health News | ) www.nbcnews.com time to read: +11 min

Now a wave of startups offer access to a new category of drugs coupled with intensive behavioral coaching online. These patients pay hundreds, if not thousands, of dollars, to access new drugs, called GLP-1 agonists, along with online coaching to encourage healthy habits. (That price includes generic drugs, but not the newer GLP-1 agonists, like Wegovy.) The firms say they’re on the vanguard of weight care, both citing the influence of biology and other scientific factors as key ingredients to their approaches. Found said older generics like zonisamide are more accessible than the GLP-1 agonists advertised on social media and their own website.

☆ UBS downgrades Teva to sell as CEO exit, ongoing litigation cloud the pharma stock's outlook
▼ + stars: | 2022-11-04 | by ( Carmen Reinicke | ) www.cnbc.com time to read: +2 min

It's time to sell Teva stock as it's facing a period of significant downside amid a phase of uncertainty, according to UBS. However, Teva's development partner Alvotech recently received an observation letter from the FDA that puts the launch date at risk, Verma wrote. Without a drug similar to Humira, there's significant downside to earnings for Teva. Price fixing risk Teva is also facing headline risk from litigation concerning price fixing, according to the note. "The DOJ price fixing case outcome may involve potential debarment from conducting business in the government channel (worse case) and/or cash settlement in the $525m-$595m range," wrote Verma.

☆ Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics
▼ + stars: | 2022-11-01 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Bourla said Pfizer is staring down an expected loss of between $16 billion and $18 billion in revenue from 2025 through 2030 as patent protections for some of its bestselling drugs expire. "We recognize that some are questioning Pfizer's longer-term growth prospects," Bourla told analysts during Pfizer's third-quarter earnings call Tuesday. Taken together, these five drugs represented about 40% of Pfizer's third-quarter revenue this year when the Covid vaccine and the antiviral treatment Paxlovid are excluded. Pfizer's RSV vaccine candidates for older adults and infants have the potential to generate billions in revenue, Bourla said. It would be the only RSV vaccine in the U.S. that protects infants by giving the shot to the mother, he said.

Pharmacies across the United States are reporting shortages of one of the most widely used antibiotics, raising concerns that the medication will be in short supply for the upcoming winter season. Three key amoxicillin manufacturers — Hikma Pharmaceuticals, headquartered in the United Kingdom; Sandoz, based in Switzerland; and Teva Pharmaceutical Industries Ltd., headquartered in Israel — are reporting shortages of the antibiotic, according to the American Society of Health-System Pharmacists, which maintains a database of drug shortages. Because amoxicillin is an antibiotic, it is not used to treat infections caused by viruses, such as Covid, the flu or RSV (respiratory syncytial virus). Pharmacists said they are worried if the shortage lingers through the winter, when infections can surge and antibiotic use typically increases. “However, there are a number of factors that can cause or contribute to drug shortages that are out of the FDA’s control.

Oct 25 (Reuters) - Biogen Inc (BIIB.O) on Tuesday said the Alzheimer's disease drug it is developing with Japan's Eisai Co Ltd (4523.T) would be used by doctors in a competitive market as investors wait for data from rival therapies made by Eli Lilly and Co (LLY.N) and Roche (ROG.S). The drug, lecanemab was shown to slow the progress of the disease by 27% in a trial last month, and additional data is expected next month. "The data needs to be seen from the other anti-amyloid therapies before we decide what is going to be meaningful," said Biogen interim research chief Priya Singhal. Its costs were about halved as the company significantly cut back on commercial infrastructure around the launch of Aduhelm, its previous Alzheimer's drug that has sputtered amid controversy over efficacy and lack of coverage by health insurers. read moreInvestors have been pinning hopes on the Alzheimer's drug as cheaper generics of Biogen's multiple sclerosis treatment Tecfidera have entered the market, hurting sales.

☆ J&J stock dip after earnings beat reflects 2022 outperformance rather than the results
▼ + stars: | 2022-10-18 | by ( Zev Fima | ) www.cnbc.com time to read: +11 min

On an adjusted operational basis, which excludes the impact of acquisitions and divestitures and currency, sales rose 8.2%. Management said on the call they continue to see this business on track for its 11th consecutive year of above-market adjusted operational sales growth in 2022. Driving the results were increased sales of Stelara on the back of market growth and market share gains in Crohn's Disease and Ulcerative Colitis. Women's Health sales increased 7.9% on an operational basis to $225 million versus the $222 million expected. On a reported basis, management tightened their EPS guidance range to $10.02 to $10.07 from $10 to $10.10 previously.

☆ Recession Fears Save Pharma From Drug-Pricing Concerns
▼ + stars: | 2022-09-26 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Some pharmaceutical companies, including Pfizer, are looking to mergers and acquisitions for strength ahead of prescription-drug price cuts later this decade. Under ordinary circumstances, the pharma industry would look like a bad place to park your money right now. The government is working to suppress drug prices through a recently signed law, and the industry is staring at a patent cliff worth more than $200 billion later this decade, as blockbuster drugs face competition from generics.

☆ Depositions of Musk, Twitter's Agrawal have been postponed -sources
▼ + stars: | 2022-09-26 | by ( ) www.reuters.com time to read: 1 min

Analysis: Novartis CEO may struggle to rally investors to Sandoz spin-off, article with imageFuture of Health · August 26, 2022Novartis CEO Vas Narasimhan could struggle to woo investors to the listing of generics drugs business Sandoz, as weaker drug prices and jittery financial markets present one of his biggest challenges in the years-long overhaul of the Swiss drugmaker.

Register now for FREE unlimited access to Reuters.com RegisterSwiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. Register now for FREE unlimited access to Reuters.com RegisterIt ranked 10th in the U.S. market last year, the company added. Novartis also said it would focus in future on five areas for investment: cardiovascular, immunology, neuroscience, solid tumors and hematology medicine. The company last month said it planned to spin off Sandoz to sharpen its focus on its patented prescription medicines. Register now for FREE unlimited access to Reuters.com RegisterEditing by Mark Potter and Jason NeelyOur Standards: The Thomson Reuters Trust Principles.

☆ Novartis to take U.S. drug patent case to Supreme Court
▼ + stars: | 2022-09-21 | by ( ) www.reuters.com time to read: +1 min

A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder/File PhotoZURICH, Sept 21 (Reuters) - Novartis AG (NOVN.S) plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug Gilenya after suffering a setback in a federal appeals court ruling, the Swiss drugmaker said on Wednesday. The ruling meant HEC Pharma and other drugmakers would potentially be able to launch a generic version of 0.5mg Gilenya imminently, pending any other judicial actions, it said. "Should generics launch in the US, we expect FY 2022 sales to be negatively impacted by USD 0.3bn. Register now for FREE unlimited access to Reuters.com RegisterReporting by Michael Shields Editing by Paul CarrelOur Standards: The Thomson Reuters Trust Principles.

☆ The Inflation Reduction Act aims to lower drug costs — but here’s how Big Pharma could get around it
▼ + stars: | 2022-09-20 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Berkeley-Lovelace-Jr.Jpg | Berkeley Lovelace Jr. | ) www.nbcnews.com time to read: +7 min

The Inflation Reduction Act is set to lower drug prices for millions of people in the United States — but experts fear pharmaceutical companies could exploit loopholes in the bill, ultimately keeping prescription costs high for many. The tactics may ultimately threaten the law’s ability to lower drug costs for consumers. Higher prices for new drugsOther experts are concerned about how companies might abuse the inflation rebate rule in the health law. The provision, which takes effect next year, imposes a rebate on drug manufacturers that raise the prices of their medications faster than inflation. By releasing new drugs at higher prices, drug companies will be able to make up for any lost revenue that they would normally receive from steadily raising prices each year, she said.

☆ Frustrated pharmacists are opting out of the insurance system, saving some customers hundreds of dollars a month
▼ + stars: | 2022-08-19 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Headshot_Small.Png | Adiel Kaplan | ) www.nbcnews.com time to read: +14 min

Hux has owned Pickerington Pharmacy, which takes nearly every kind of insurance, since 2016. For some drugs, especially name-brand medications without generic alternatives, the insurance pharmacy, Pickerington, will most likely be the better bet. For other drugs, particularly those that have recently gone generic, it will be the all-cash pharmacy, Freedom. Or is it the noninsurance world?”For Kitchen, a retired registered nurse with arthritis and fibromyalgia, it was the noninsurance world of Freedom Pharmacy. By cutting out the middlemen, Freedom Pharmacy is far cheaper to operate.

Here are nine questions we look to answer before adding a new name to our portfolio. Let's use our recent initiation of Procter & Gamble as an example. For example, we believe that consumer products such as those made and sold by Procter & Gamble are about as durable as they get. In the case of Procter & Gamble, we acknowledge we are paying above the five-year historic average valuation. In the case of Procter & Gamble, one potential red flag would be that current liabilities, those due within the next 12 months, exceed current assets.

Search resuls for: "generics"

14 mentions found